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A novel inhibition assay is proposed by capillary 1 
electrophoresis/dynamic frontal analysis (CE/DFA). When a 2 
substrate of p-nitrophenyl phosphate and an inhibitor of 3 
theophylline were tandemly introduced into the capillary 4 
containing alkaline phosphatase as an enzyme, two plateau 5 
signals were detected in the electropherogram. A higher 6 
plateau is based on the CE/DFA without inhibition, and a 7 
suppressed plateau is formed under the inhibition while the 8 
substrate zone passing through the inhibitor zone. Inhibition 9 
constant was successfully determined through the two plateau 10 
heights.  11 
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Enzyme assays including reaction kinetics have been 15 
analyzed in a homogeneous batch solution for a long time. 16 
Michaelis-Menten kinetic analysis is one of the major targets, 17 
and Michaelis-Menten constant (KM) is an essential 18 
parameter for enzymes. Recently, capillary electrophoretic 19 
methods have been proposed for the enzyme assays by in-20 
capillary reactions.1-4 The analysis methods by capillary 21 
electrophoresis (CE) are classified in electrophoretically 22 
mediated microanalysis (EMMA),5-11 in-capillary 23 
immobilized enzyme reactor (IMER),11-15 and transverse 24 
diffusion of laminar flow profiles (TDLFP).8,10 In most of the 25 
analyses, the substrate and the product are electrophoretically 26 
resolved and the peak signals have been used for the 27 
quantifications and for the analysis of the enzyme assays. 28 
When a zone of an enzyme solution was introduced into the 29 
separation buffer containing a substrate, a plateau signal was 30 
detected as the result of the footprint of the enzyme passing 31 
through the substrate solution.16-18 The plateau heights were 32 
used for the enzyme assays.  33 
The present authors have proposed a different format of 34 
EMMA.19 A substrate solution is injected into a separation 35 
capillary, where the separation buffer contains an enzyme. 36 
Along with the electrophoretic migration of the substrate 37 
zone in the separation buffer, the substrate continuously 38 
reacts with the enzyme and the formed product is 39 
continuously resolved from the substrate zone. The product 40 
is kinetically formed at a constant reaction rate, and thus, the 41 
product is detected as a plateau signal from the start of the 42 
reaction to the detection time of the substrate. The height of 43 
the plateau signal is directly related with the reaction rate, and 44 
it is used for the enzyme assay. The plateau signal is based on 45 
the continuous resolution of the product from the substrate 46 
zone under the zero-order kinetic reaction of an enzyme, and 47 
the analysis method is named as capillary 48 
electrophoresis/dynamic frontal analysis (CE/DFA).19 A 49 
main advantage of CE/DFA is the continuous resolution of 50 
the product from the substrate−enzyme zone, which 51 
eliminates the interference from the product on the enzyme 52 
reaction.  53 
In this study, the present authors propose a novel 54 
inhibition assay using CE/DFA. The schematic diagram of 55 
the inhibition by CE/DFA is shown in Figure 1. A substrate 56 
solution (S) and an inhibitor solution (I) are tandemly 57 
introduced into the capillary filled with a separation buffer 58 
containing an enzyme (Figure 1a). Both zones of the substrate 59 
and the inhibitor electrophoretically migrate in the separation 60 
buffer at different velocity, and the inhibition occurs when 61 
the two zones overlap (Figure 1c). While the reaction product 62 
(P) continuously generated is detected as a plateau signal, the 63 
height of the plateau signal is suppressed by the inhibition 64 
with the reduced amount of the product. Consequently, an 65 
electropherogram of two-steps plateau signal can be detected, 66 
as shown in Figure 1e. The characteristic in the CE/DFA 67 
format is that both the inhibition and no inhibition can 68 
simultaneously be detected in one electropherogram.  69 
70 
71 
Figure 1.  Schematic diagram of the inhibition in CE/DFA by the tandem 72 
injections of a substrate and an inhibitor solutions (a) − (d), and a typical 73 
electropherogram (e). The inhibition occurs when the zones of a substrate 74 
(S) and an inhibitor (I) overlap by the electrophoretic migration. E: an 75 
enzyme contained in the separation buffer.  76 
Alkaline phosphatase (ALP, EC 3.1.3.1) catalyzes the 77 
hydrolysis of phosphoric monoester to give phosphoric acid 78 
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and an alcohol. ALP plays an important role in human 1 
skeletal mineralization,20 and ALP assays have intensely been 2 
studied.21,22 Theophylline is a well-known inhibitor of ALP, 3 
and it is often used as a model inhibitor for ALP assays.16,23,24 4 
Since the enzymatic reaction of ALP and the inhibition of 5 
theophylline are well established, they are adopted in this 6 
study. p-Nitrophenyl phosphate (NPP) was used as a 7 
substrate, and the hydrolysis product of p-nitrophenolate 8 
(NP) was photometrically detected.  9 
Alkaline phosphatase from bovine intestinal mucosa 10 
was purchased from Sigma-Aldrich. A substrate of NPP as 11 
disodium salt hexahydrate, and a hydrolysis product of NP 12 
were from Fujifilm Wako Pure Chemical. An inhibitor of 13 
theophylline was from Tokyo Chemical Industry. Other 14 
reagents used were of analytical grade. All solutions were 15 
prepared with deionized water purified by Milli-Q Gradient 16 
A10.  17 
A 3DCE system (Agilent Technologies) equipped with a 18 
photodiode array detector was used as a CE system. A fused 19 
silica capillary held in a capillary cartridge was used as a 20 
separation capillary with its dimensions of 75 m i.d., 375 21 
m o.d., 64.5 cm in total length, and 56 cm in effective length 22 
from the injection end to the detection point. A ChemStation 23 
program (Agilent Technologies, Ver. B04.02) was used for 24 
the control of the CE system and the data analysis.  25 
A separation buffer was prepared with 0.01 mol L−1 26 
borax with its pH controlled at 9.8 with NaOH. An enzyme 27 
of ALP was contained in the separation buffer at 0.55 unit 28 
mL−1. After the capillary filled with the separation buffer, 29 
solutions of a substrate NPP, the separation buffer, and an 30 
inhibitor of theophylline were tandemly injected into the 31 
capillary from the anodic end by applying pressure, as shown 32 
in Figure 1a. Both ends of the capillary were dipped in the 33 
buffer vials, and a DC voltage of 25 kV was applied to the 34 
capillary for the electrophoresis. The hydrolysis product of 35 
NP was photometrically detected at 400 nm. During the 36 
experiments, the capillary, as well as the buffer vials were 37 
thermostat at 37 oC. 38 
Michaelis-Menten kinetic analysis was made with the 39 
plateau heights of the generated NP in the electropherograms. 40 
Lineweaver-Burk plots were made to determine the 41 
Michaelis-Menten constant (KM) and the inhibition constant 42 
(KI).  43 
Both the injection sequence and the migration order of 44 
the substrate and the inhibitor are the key factors on 45 
examining the inhibition assay by CE/DFA. The enzymatic 46 
hydrolysis continuously proceeds during the migration of the 47 
substrate zone in the separation buffer, providing plateau 48 
signal of the product, as shown in Figure 1b.19 The 49 
electrophoretic mobility of a substrate NPP and a product of 50 
NP are different with each other, and the injected zones 51 
migrate in the capillary at the different velocity. Theophylline 52 
as an inhibitor and the substrate of NPP possess the charge of 53 
−1 and −2 respectively under the enzymatic reaction 54 
conditions of pH 9.8. The backward velocity of NPP is faster 55 
than theophylline, and the order of the forward velocity is in 56 
the order of theophylline > NPP under a fast electroosmotic 57 
flow (EOF). Thus, the injection sequence is in the order of a 58 
substrate NPP, the separation buffer to divide the two zones, 59 
and an inhibitor theophylline, as shown in Figure 1a. The 60 
inhibition with the inhibitor occurs in the CE/DFA, when the 61 
inhibitor zone is overlapping on the substrate zone, as is 62 
shown in Figure 1c; the passing of the inhibitor zone over the 63 
substrate zone is essential for the inhibition assay by CE/DFA. 64 
An electropherogram was obtained with such an injection 65 
sequence, as shown in Figure 2. In this electropherogram, the 66 
detection wavelength was set at 200 nm to detect all of the 67 
substrate NPP, the product NP, and the inhibitor theophylline. 68 
It can be seen from the electropherogram that the 69 
theophylline as an injected zone is firstly detected as a peak 70 
signal, then the product NP detected as a plateau signal, and 71 
finally the injected NPP detected as a peak signal. A plateau 72 
signal of NP suggests that NPP is continuously hydrolyzed 73 
with ALP during the electrophoresis. A dipped plateau is 74 
detected in the electropherogram with an arrow. The 75 
enzymatic hydrolysis would be inhibited with theophylline 76 
during the electrophoretic migration of the injected zones and 77 
their overlapping. A dipped signal of the product has been 78 
detected by an enzymatic reaction of ALP by injecting an 79 
enzyme zone and an inhibitor zone, where a fluorescent 80 
substrate has been contained in the running buffer.17 The 81 
inhibition occured when the enzyme zone and the inhibitor 82 
zone overlap. However, the dipped signal was not plateau and 83 
simultaneous determinations of KM and KI were not achieved 84 
by such sequence.17 Although KM and KI were simultaneously 85 
determined by Crawford, et al., it was necessary to stop the 86 
electrophoresis once for the enzymatic reaction.25  87 
 88 
 89 
Figure 2.  Typical electropherogram in CE/DFA accompanying 90 
inhibition. A substrate of NPP and an inhibitor of theophylline were 91 
tandemly injected into the capillary. A dipped plateau by the inhibition 92 
is detected in the plateau range of the formed NP. Concentration of NPP 93 
in the injected zone: 1.0 mmol L−1. Concentration of theophylline in the 94 
injected zone: 1.0 mmol L−1.  95 
It is essential for the inhibition assay to detect the dipped 96 
region as a clear plateau. The injection period of the 97 
theophylline zone was examined in the range between 10 s 98 
and 40 s to control the overlapping time on the NPP zone. 99 
The results are shown in Figure 3. The detection wavelength 100 
was set at 400 nm, and only the product of NP was detected. 101 
The difference in the detection time of the plateau signal is 102 
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due to the injection period. It is noticed from Figure 3 that the 1 
dipped plateau came to be wide by extending the injection 2 
period of the theophylline solution. However, the dipped 3 
plateau with theophylline inhibition is not suitable over the 4 
injection period of 30 s. It would be because the precedent 5 
injected zone of the substrate dispersed seriously by the long-6 
time pressure injection. Therefore, the injection time of 7 
theophylline was set at 20 s.  8 
 9 
 10 
Figure 3.  CE/DFA electropherograms of NPP with ALP under tandem 11 
injections of NPP and theophylline. The injection order of the solutions 12 
was: 2.0 mmol L−1 NPP as a substrate for 5 s, the separation buffer for 13 
10 s, and 1.0 mmol L−1 theophylline as an inhibitor. Injection period of 14 
theophylline: (a) 10, (b) 20, (c) 30, and (d) 40 s. Black arrows indicate 15 
the inhibition with theophylline. *: NP generated in the NPP solution 16 
before the electrophoresis. The separation buffer and the CE conditions 17 
are written in the text.  18 
The injection period of the separation buffer dividing 19 
the substrate zone and the inhibitor zone was also examined. 20 
Aim of dividing the substrate zone and the inhibitor zone is 21 
to delay the overlapping time from the start of the 22 
electrophoresis. Because the substrate NPP sometimes 23 
degraded to form NP before the CE/DFA measurements, as 24 
well as by the contact of substrate plug and electrophoretic 25 
buffer just before applying the voltage, the contaminated NP 26 
would interfere with the dipped plateau as shown in the 27 
asterisks in the electropherograms. The injection period of the 28 
separation buffer was examined in the range between 5 s and 29 
40 s; the results are shown in Figure 4. With the extension of 30 
the injection period of the separation buffer, it is possible to 31 
resolve the contaminated NP (*) and the dipped plateau. 32 
Longer injection period of the separation buffer would 33 
promote the dispersion of the injected zones, and an injection 34 
period of 10 s was chosen for the separation buffer. In this 35 
way, a clear suppressed plateau is detected by controlling the 36 
injection sequence and the injection periods.  37 
 38 
 39 
Figure 4.  CE/DFA electropherograms of NPP with ALP under tandem 40 
injections of NPP and theophylline. The injection order of the solutions 41 
is: 2.0 mmol L−1 NPP for 5 s, the separation buffer, and 1.0 mmol L−1 42 
theophylline for 20 s. Injection period of the separation buffer: (a) 5, (b) 43 
10, (c) 20, and (d) 40 s. Black arrows indicate the inhibition with 44 
theophylline. *: NP generated before the electrophoresis. The separation 45 
buffer and the CE conditions are the same as in Figure 3. 46 
The two plateau heights were reproducible with 7 47 
repeated measurements, and no plateau response was 48 
detected with the separation buffer without the enzyme after 49 
several CE/DFA measurements. Thus, adsorption of the 50 
enzyme to the inner wall of the capillary is not significant. 51 
Michaelis-Menten kinetic analysis was examined for 52 
the determinations of KM and KI values through the plateau 53 
signals. The height of the product plateau was used for the 54 
analysis instead of the reaction rate.19 The product plateaus 55 
were obtained at different NPP concentrations from 0.4 mmol 56 
L−1 to 3.0 mmol L−1, where the concentration of an inhibitor 57 
theophylline was set at 0.5 mmol L−1 or 1.0 mmol L−1. The 58 
electropherograms obtained with 1.0 mmol L−1 theophylline 59 
are shown in Figure 5. Two-steps of the plateau height were 60 
detected in the electropherograms. The plateau height 61 
without inhibition (higher plateau) increased with the 62 
increase in the NPP concentrations, as previously reported.19 63 
The plateau height under inhibition (lower plateau) also 64 
increased with the increase in the NPP concentrations, but the 65 
height is lower than the higher plateau because of the 66 
inhibition.  67 
Lineweaver-Burk plots were made to determine the 68 
Michaelis-Menten constant (KM) and the inhibition constant 69 
(KI). Since the plateau height as absorbance response is 70 
directly related with the kinetic reaction rate, it was used for 71 
the analysis instead of the reaction rate. The plateau height, 72 
however, gradually decreases with the reaction time, i.e., the 73 
late detection time. It is because of the gradually reduced 74 
substrate concentration by the enzymatic reaction. Therefore, 75 
the highest response of the plateau was used for the analysis. 76 
The results are shown in Figure 6. The KM value was 77 
determined through the x-intercept of the signal heights of the 78 
higher plateau (● in Figure 6); the KM value was 1.59 mmol 79 
L−1. The Km value determined in this study agreed with the 80 
reported ones; 0.4 mmol L−1 23 or 1.5 mmol L−1.26 It is noticed 81 
from Figure 6 that the Lineweaver-Burk plots are parallel 82 




(lower plateau) of theophylline. The parallel lines suggest 1 
that the inhibition form of theophylline is uncompetitive. The 2 
uncompetitive form of the inhibition agrees with the reported 3 
result.23,24 The inhibition constant of theophylline as an 4 
uncompetitive inhibitor, KI, can be determined using eq. (1).
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The KI value determined in this study was 0.72 mmol L
−1. 15 
The value also agreed with the reported values, 0.1 mmol L−1 16 
17 or 0.69 mmol L−1.23  17 
 18 
 19 
Figure 5.  CE/DFA electropherograms of NPP with ALP under tandem 20 
injections of NPP and theophylline at different concentrations of NPP. 21 
Concentrations of NPP: (a) 0.4, (b) 1.0, (c) 1.5, (d) 2.0 mmol L−1. 22 
Concentrations of theophylline: 1.0 mmol L−1. The injection sequence of 23 
the sample solutions is: substrate soln. for 5 s, separation buffer for 10 s, 24 
and inhibitor soln. for 20 s. The separation buffer and the CE conditions 25 
are the same as in Figure 3. 26 
 27 
Figure 6.  Lineweaver-Burk plots for the enzymatic hydrolysis of NPP 28 
with ALP by the inhibition with theophylline. Theophylline 29 
concentrations: ●, none (higher plateau); ▲, 0.5 mmol L−1; ■, 1.0 mmol 30 
L−1. The injection sequence, the separation buffer, and the CE conditions 31 
are the same as in Figure 5.  32 
In conclusion, a novel inhibition assay of enzymatic 33 
reaction is proposed by CE/DFA. It is demonstrated that 34 
dynamic reactions in a capillary led to the plateau signals in 35 
CE/DFA. Two plateau signals are detected in this CE/DFA 36 
by the tandem injections of a substrate and an inhibitor 37 
solutions, as well as by their electrophoretic migration. By 38 
using the two plateau heights, both KM and KI values can 39 
simultaneously be determined by a series of the 40 
measurements. Zero-order kinetic reactions with an 41 
inhibition reaction would be analyzed by this format of 42 
CE/DFA.  43 
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